NCT05527912招募中2 期
A Single-arm、Multicenter、Open-label、Phase II Clinical Study of the Combination of Rituximab、Chidamide、Zanubrutinib-induced and CHOP Therapy for Untreated Dual-expressing Diffuse Large B Cell Lymphoma
Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2023年2月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- EOT-CRR
研究概览
简要总结
This phase II trial studies how well giving rituximab,chidamide, and zanubrutinib with Sequential chemotherapy works in treating patients with double express diffuse large B-cell lymphoma. The prognosis of patients with DEL-DLBCL is usually worse than that of ordinary DLBCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed dual-expression diffuse large B-cell lymphoma (DLBCL) with IHC BCL2 expression ≥50% and MYC expression ≥40%.
- •Male or female patients: 18-65 years old.
- •ECOG physical status score: 0~2 points.
- •Estimated survival time ≥6 months.
- •There must be at least 1 evaluable or measurable lesion that meets Lugano 2014 criteria [ evaluable lesion : 18F-fluorodeoxyglucose/Positron Emission Tomography (18FDG/PET) examination showed elevated lymph node or extranodal local uptake (higher than liver) and PET and/or Computed Tomography (CT) features consistent with lymphoma. Measurable lesion : Nodules >15mm or extranodal lesions >10mm with increased 18FDG uptake]. The absence of measurable lesions and increased diffuse hepatic uptake of 18FDG should be excluded.
- •Major organ function was good, that is, the following requirements should be met one week before enrollment: blood routine, WBC≥3×10*9/L, Hb≥80g/L,PLT≥80×10*9/L; The heart and liver functions were normal (TBIL≤1.5ULN, ALT and AST ≤2.5ULN), renal function was normal (1.5 times serum Cr≤1.5ULN), and no coagulation abnormalities were observed.
- •LVEF≥50% by echocardiography.
- •Women of childbearing age must have a pregnancy test (serum or urine) with a negative result within 14 days before enrollment and be willing to use a reliable method of contraception during the trial.
- •Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.
排除标准
- •Special types of DLBCL: DLBCL associated with chronic inflammation, lymphomatoid granuloma, primary mediastinal large B-cell lymphoma, B-cell lymphoma that cannot be classified (with intermediate features between DLBCL and classical Hodgkin's lymphoma), and primary central nervous system (CNS) DLBCL.
- •Transformed DLBCL (such as follicular lymphoma, chronic lymphocytic leukemia/small B-cell lymphoma transformed DLBCL), secondary central nervous system invasion of DLBCL.
- •A history of malignancies other than squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or carcinoma in situ of the cervix within the past 5 years.
- •Major surgical procedures (excluding diagnostic procedures) performed within the past 2 months.
- •Previous NHL treatment: including chemotherapy, immunotherapy, radiotherapy, monoclonal antibody therapy, surgical treatment (except diagnostic surgery and biopsy).
- •Previous treatment with cytotoxic drugs or mab CD20 antibodies for other diseases (e.g., rheumatoid arthritis).
- •Those who used any monoclonal antibody within 3 months before enrollment, participated in other clinical trials and used other trial-related drugs, and were vaccinated with (attenuated) live virus vaccine within 1 month before enrollment.
- •Had used hematopoietic cytokines within 2 weeks before enrollment.
- •Patients with suspected active or latent tuberculosis.
- •Personswith known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding fungal infections of the nail bed skin) or any major systemic infection event requiring intravenous antibiotic treatment or hospitalization within 4 weeks prior to enrollment (except neoplastic fever) .
- •Hiv-positive persons. Active HBV-positive and HCV-positive individuals, but those whose disease was judged to be under control, should be enrolled with caution, but should undergo effective antiviral intervention.
- •Other serious medical conditions that may limit the subject's participation in the study, such as uncontrolled diabetes; Severe cardiac insufficiency (NYHA grade II or above); Acute coronary syndrome in the last 6 months; Coronary revascularization such as stenting, cabG, and other cardiac and macrovascular procedures within the last 6 months; Severe arrhythmias include frequent ventricular premature, ventricular tachycardia, rapid atrial fibrillation/flutter, and severe bradycardia. （Uncontrolled hypertension: greater than 150/100mmHg). Gastric ulcers (those identified by the investigators as being at risk for perforation); Active autoimmune diseases; Severe hypertension; Patients with severe respiratory disease (e.g., obstructive pulmonary disease and history of bronchospasm), such as patients with a known history of interstitial pneumonia or a high suspicion of interstitial pneumonia; Or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
- •Contraindications for any of the study drugs, including previous anthracyclines; Patients with diabetes who could not tolerate prednisone in this protocol.
- •Subject has a history of alcohol or drug abuse.
- •Persons with allergies or known allergies to any pharmaceutical active ingredient, excipient, or murine product or xenogeneic protein included in this test.
- •People with severe mental illness.
- •Patients who were unable to comply during the trial and/or follow-up phase.
- •Patients unable to swallow the study drug properly. Those who were deemed ineligible by the researchers.
研究组 & 干预措施
Arm I (RCZ WITH CHOP)
Experimental
Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy
干预措施: Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy (Drug)
结局指标
主要结局
EOT-CRR
时间窗: 12 months
End of Treatment Complete Response Rate
次要结局
- EOT-ORR(12 months)
- EOT-CRR2(2 months)
- 2year-OS(24 months)
- 2year-PFS(24 months)
研究者
Li Zhiming
LiZhiming
Sun Yat-sen University
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaLiver LymphomaMantle Cell LymphomaNCT04115631ECOG-ACRIN Cancer Research Group360
进行中（未招募）
2 期
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Mucosa-associated Lymphoid Tissue Lymphoma (MALT)NCT06647732Sun Yat-sen University42
Unknown
不适用
Rituximab Combined With Chidamide and Lenalidomide for r/r AITLAngioimmunoblastic T-cell LymphomaChemotherapy EffectChemotherapeutic ToxicityNCT04319601Zhejiang Cancer Hospital26
招募中
2 期
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DELDouble-expressor LymphomaNCT06674096Zhejiang Cancer Hospital44
已完成
2 期
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibDiffuse Large B-Cell Lymphoma UnclassifiableNCT02636322M.D. Anderson Cancer Center60